Want to see TRAX full AI Analyst Report?

First Tracks Biotherapeutics Inc (TRAX) Price & Analysis

42 Followers

TRAX Stock Chart & Stats

$45.50

Market closed

$45.50

Day’s Range― - ―

52-Week Range$14.72 - $49.91

Previous CloseN/A

VolumeN/A

Average Volume (3M)N/A

Market Cap

$1.57B

Enterprise Value$385.53M

Total Cash (Recent Filing)$286.45M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.20

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding35,730,843

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)2.30

Price to Sales (P/S)0.00

P/FCF Ratio-4.62

Enterprise Value/Market Cap0.25

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-7.32

Forecast

1Y Price Target

$66.00

Price Target Upside45.05% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageA very low debt-to-equity ratio reduces refinancing and interest-rate pressure, giving management durable financial flexibility. Over the next several months this conservatism lowers default risk and preserves the ability to fund R&D or strategic moves without creditor constraints.

Substantial Equity CushionAlthough equity has declined, a $287.5M equity base still provides a meaningful balance-sheet buffer to absorb losses and support operations. This tangible cushion extends runway and reduces immediate pressure to secure dilutive financing if cash management is tightened.

Improving Free Cash Flow TrendAn improvement in free cash flow growth, even from negative levels, signals early progress in converting spending into better cash outcomes. If sustained, this trend can materially reduce future funding needs, lowering dilution risk and supporting longer-term program funding.

Bears Say

No Revenue GenerationThe absence of revenue means the business lacks commercial cash inflows to offset R&D and operating expenses. Structurally dependent on external financing or milestone receipts, the company faces sustained dilution and execution risk until it achieves product commercialization.

Heavy And Worsening Cash BurnLarge and increasing negative operating cash flow shows the company is consuming cash rapidly to fund operations. Worsening burn elevates the probability of near-term financing, increases dilution risk and constrains capacity to advance multiple programs simultaneously.

Eroding Equity And Negative ROEDeclining equity and sharply negative returns on equity indicate capital is being consumed without generating shareholder returns. Continued erosion narrows strategic options, weakens the balance sheet over time and increases the likelihood of financing on unfavorable terms.

First Tracks Biotherapeutics Inc News

First Tracks Biotherapeutics reports Q2 EPS (95c), consensus (80c)

“First Tracks continues to execute against a broad development strategy for our potentially best-in-class CD122 antagonist, ANB033, and...

3d ago

TRAX

First Tracks Biotherapeutics price target raised to $65 from $48 at Barclays

Barclays raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $65 from $48 and keeps an...

3d ago

TRAX

First Tracks price target raised to $57 from $44 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $57 from $44 and keeps...

3d ago

TRAX

First Tracks Biotherapeutics price target raised to $95 from $54 at Piper Sandler

Piper Sandler raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $95 from $54 based on...

3d ago

TRAX

First Tracks Biotherapeutics management to meet with Piper Sandler

Meeting to be held on August 17-18 hosted by Piper Sandler. Published first on TheFly – the ultimate...

10d ago

TRAX

First Tracks Biotherapeutics price target raised to $65 from $45 at UBS

UBS raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $65 from $45 and keeps a...

10d ago

TRAX

First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush

Wedbush raised the firm’s price target on First Tracks Biotherapeutics to $60 from $30 and keeps an Outperform...

23d ago

ARGX

FBRX

First Tracks Biotherapeutics price target raised to $55 from $30 at Wells Fargo

Wells Fargo analyst Derek Archila raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $55 from...

23d ago

FBRX

TRAX

After Forte acquisition, H.C. Wainwright says First Tracks could be target

After Argenx (ARGX) announced a deal to acquire Forte (FBRX) for a price of $77 per share, a...

24d ago

ARGX

FBRX

First Tracks Biotherapeutics: Buy Rating Reaffirmed with Unchanged $44 Price Target on ANB033 CD122-Targeting Upside and Acquisition Potential

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on First Tracks Biotherapeutics Inc, retaining the price...

24d ago

TRAX

First Tracks Biotherapeutics price target raised to $48 from $40 at Barclays

Barclays raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $48 from $40 and keeps an...

1M ago

TRAX

Buy Rating on First Tracks (TRAX) Driven by Strengthening IL-15/CD122 Pathway Validation and Upcoming ANB033 Clinical Catalysts in Celiac Disease and Vitiligo

In a report released yesterday, Emily Bodnar from H.C. Wainwright maintained a Buy rating on First Tracks Biotherapeutics...

1M ago

TRAX

Emily Bodnar Reiterates Buy on AnaptysBio, Keeps $30 Price Target on ANB033 Progress and Solid Cash Runway

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on First Tracks Biotherapeutics Inc, retaining the price...

3M ago

TRAX

TRAX: Event-Driven Immunology Catalyst Play With Differentiated Pipeline and Valuation Upside Supporting Buy Rating

David Risinger, an analyst from Leerink Partners, has initiated a new Buy rating on First Tracks Biotherapeutics Inc...

4M ago

TRAX

TRAX FAQ

What was First Tracks Biotherapeutics Inc’s price range in the past 12 months?

First Tracks Biotherapeutics Inc lowest stock price was $14.72 and its highest was $49.91 in the past 12 months.

What is First Tracks Biotherapeutics Inc’s market cap?

First Tracks Biotherapeutics Inc’s market cap is $1.57B.

When is First Tracks Biotherapeutics Inc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were First Tracks Biotherapeutics Inc’s earnings last quarter?

Currently, no data Available

Is First Tracks Biotherapeutics Inc overvalued?

According to Wall Street analysts First Tracks Biotherapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does First Tracks Biotherapeutics Inc pay dividends?

First Tracks Biotherapeutics Inc does not currently pay dividends.

What is First Tracks Biotherapeutics Inc’s EPS estimate?

First Tracks Biotherapeutics Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does First Tracks Biotherapeutics Inc have?

First Tracks Biotherapeutics Inc has 35,730,843 shares outstanding.

What happened to First Tracks Biotherapeutics Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of First Tracks Biotherapeutics Inc?

Currently, no hedge funds are holding shares in TRAX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

First Tracks Biotherapeutics Inc Stock Smart Score

Neutral

Company Description

First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

First Tracks Biotherapeutics Inc (TRAX) Earnings & Revenues

Historic Earnings Reports

TRAX Stock 12 Month Forecast

Average Price Target

$66.00

▲(45.05% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","96":"$96","36.75":"$36.8","56.5":"$56.5","76.25":"$76.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$66.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$55.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,36.75,56.5,76.25,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.04,47.96,51.879999999999995,55.8,59.72,63.64,67.56,71.47999999999999,75.4,79.32,83.24000000000001,87.16,91.08,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.04,45.72923076923077,47.418461538461536,49.107692307692304,50.79692307692308,52.48615384615385,54.175384615384615,55.864615384615384,57.55384615384615,59.24307692307693,60.93230769230769,62.621538461538464,64.31076923076924,{"y":66,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.04,44.88307692307692,45.72615384615384,46.56923076923077,47.41230769230769,48.255384615384614,49.098461538461535,49.941538461538464,50.784615384615385,51.62769230769231,52.47076923076923,53.31384615384616,54.15692307692308,{"y":55,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.38,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.09,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.59,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Similar Stocks

XNCR

Xencor

―

CTMX

CytomX Therapeutics

―

KURA

Kura Oncology

―

REPL